Abstract

Metallothioneins (MT) are a family of low molecular weight proteins that are silenced during colorectal cancer progression, mainly through epigenetic mechanisms, and this loss is associated with poor survival. In this article, we show that overexpression of the MT1G isoform sensitizes colorectal cell lines to the chemotherapeutic agents oxaliplatin (OXA) and 5-fluorouracil (5-FU), in part through enhancing p53 and repressing NF-κB activity. Despite being silenced, MTs can be reinduced by histone deacetylase inhibitors such as trichostatin A and sodium butyrate. In fact, this induction contributes to the cytotoxicity of these agents, given that silencing of MTs by siRNAs reduces their growth-inhibitory activities. Zinc ions also potently enhance MT expression and are cytotoxic to cancer cells. We show for the first time that OXA and 5-FU induce higher levels of intracellular labile zinc, as measured using the fluorescent probe FLUOZIN-3, and that such zinc contributes to the activation of p53 and repression of NF-κB. Addition of zinc enhanced growth inhibition by OXA and 5-FU, and was also capable of resensitizing 5-FU-resistant cell lines to levels comparable with sensitive cell lines. This effect was MT independent because silencing MTs did not affect zinc cytotoxicity. In conclusion, we show that MT induction and zinc administration are novel strategies to sensitize colorectal cancer cells to presently utilized chemotherapeutic agents.

Highlights

  • Colorectal cancer is the third most frequent cancer worldwide, having a mortality rate near 50% [1]

  • Given the proposed roles for MTs in apoptosis and drug detoxification, we studied whether MT1Gþ lines differed in their susceptibility to two of the most widely used chemotherapeutic agents in colorectal cancer, OXA and 5-FU (5-FU)

  • We have shown that MT1G expression sensitizes colorectal cancer cell lines to OXA and 5-FU treatments

Read more

Summary

Introduction

Colorectal cancer is the third most frequent cancer worldwide, having a mortality rate near 50% [1]. Current therapeutic strategies rely heavily on complete surgical removal of the tumor, despite which 40% of patients recur. Chemotherapeutic adjuvant treatment in stage II disease is controversial and improves overall survival by 22% in stage III. Overall 5-year survival rates for stage IV patients are less than 10% [2]. Therapeutic regimens are mainly based on 5-fluorouracil (5FU), oxaliplatin (OXA), and irinotecan, all of which produce considerable side effects. It is of paramount importance to develop new therapies or to improve currently available agents

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call